Akeso Inc. obtained IND clearance from China’s National Medical Products Administration for AK-150, a first-in-class trispecific antibody targeting advanced solid tumors. The approval authorizes Akeso to begin clinical evaluation in China, enabling dose-finding and early safety studies for the trispecific candidate. Akeso will proceed to patient enrollment under NMPA oversight, advancing its pipeline of next-generation antibody therapeutics aimed at solid tumor indications.